Synergy Pharmaceutical announced a presentation on SP-333, the company's second investigational drug from the guanylate cyclase-C agonist class, at the American College of Gastroenterology 77th annual meeting, which is being held in Las Vegas, NV from October 19-24. The presentation highlights pioneering research demonstrating that SP-333 ameliorates colitis in mice through inhibition of NF-kappa B activation. SP-333 recently entered clinical trials as an experimental drug for the treatment of ulcerative colitis, and is presently in a Phase I trial in healthy volunteers.
- Pharmaceuticals & Drug Trials
- investigational drug